
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
Downers Grove, IL-Vysis, Inc. has received FDA approval to market itsUroVysion assay for monitoring bladder cancer recurrence.





